0 0 0
This online shop is using cookies to give you the best shopping experience. Thereby for example the session information or language setting are stored on your computer. Without cookies the range of the online shop's functionality is limited. If you don't agree, please click here.

Kim Management of Advanced Prostate Cancer

ISBN: 978-981-10-6942-0

Edition: 1st Ed.

Publication date: July 2018

Cover: Hardcover

Pages: 201 p.

Illustrations: 11 ill.

Publisher: Springer

Delivery times, dependent on availability and publisher: between 2 and 14 days from when you complete the order.

Description

  • Summarizes the state of the art in the management of locally advanced and metastatic prostate cancer
  • Evaluates the role of abiraterone and enzalutamide, docetaxel-based chemotherapy, and novel agents
  • Discusses surgical approaches and the role of adjuvant and neoadjuvant therapy
  • Examines current radiotherapy techniques

This textbook summarizes the state of the art in the management of locally advanced and metastatic prostate cancer with the aim of providing the knowledge required for optimal treatment decision making in individual cases. Readers will find comprehensive coverage of the latest developments in surgery, radiotherapy, androgen deprivation therapy (ADT), chemotherapy, and immunotherapy. The role of the hormonal therapies abiraterone and enzalutamide and docetaxel-based chemotherapy in castration-resistant prostate cancer and hormone-sensitive metastatic disease is carefully evaluated. Among the other therapies discussed are LHRH agonists and antagonists, cabazitaxel, radium-223, and various novel agents still under clinical trials. The section on surgical approaches addresses, among other topics, the use of robot-assisted radical prostatectomy, pelvic lymphadenectomy, and the benefits of adjuvant and neoadjuvant therapy. The current role of external beam radiotherapy, alone or in combination with ADT and brachytherapy, for locally advanced disease is reviewed. Management of Advanced Prostate Cancer will be a valuable resource for practitioners at all levels of expertise.